ASAnders Sundqvist

Anders Sundqvist

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anders Sundqvist has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Hans van Dam

    Department of Cell and Chemical Biology Leiden University Medical Center (LUMC) Einthovenweg 20 2333ZC Leiden The Netherlands

    3 shared publications
  • Aristidis Moustakas

    Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden

    2 shared publications
  • Carl-Henrik Heldin

    Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

    2 shared publications
  • Eleftheria Vasilaki

    Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

    2 shared publications
  • Kohei Miyazono

    Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

    2 shared publications
  • Masato Morikawa

    Division of Health Science, Advanced Comprehensive Research Organization (ACRO), Teikyo University, Itabashi-ku, Tokyo 173-0003, Japan; Department of Molecular Pathology; Department of Applied Pathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan

    2 shared publications

Latest Publications

  • Open Access

    Mast cell chymase has a negative impact on human osteoblasts

    by Thomas Lind, Fabio Rabelo Melo, Ann-Marie Gustafson, Anders Sundqvist, Xinran O Zhao, Aristidis Moustakas, Håkan Melhus, Gunnar Pejler


  • Open Access

    TGFβ and EGF signaling orchestrates the AP-1- and p63 transcriptional regulation of breast cancer invasiveness

    by Anders Sundqvist, Eleftheria Vasilaki, Oleksandr Voytyuk, Yu Bai, Masato Morikawa, Aristidis Moustakas, Kohei Miyazono, Carl-Henrik Heldin, Peter Ten Dijke, Hans van Dam

    Activator protein (AP)-1 transcription factors are essential elements of the pro-oncogenic functions of transforming growth factor-β (TGFβ)-SMAD signaling. Here we show that in multiple HER2+ and/or EGFR+ breast cancer cell lines these AP-1-dependent tumorigenic properties of TGFβ critically rely on epidermal growth factor receptor (EGFR) activation and expression of the ΔN isoform of transcriptional regulator p63. EGFR and ΔNp63 enabled and/or potentiated the activation of a subset of TGFβ-inducible invasion/migration-associated genes, e.g., ITGA2, LAMB3, and WNT7A/B, and enhanced the recruitment of SMAD2/3 to these genes. The TGFβ- and EGF-induced binding of SMAD2/3 and JUNB to these gene loci was accompanied by p63-SMAD2/3 and p63-JUNB complex formation. p63 and EGFR were also found to strongly potentiate TGFβ induction of AP-1 proteins and, in particular, FOS family members. Ectopic overexpression of FOS could counteract the decrease in TGFβ-induced gene activation after p63 depletion. p63 is also involved in the transcriptional regulation of heparin binding (HB)-EGF and EGFR genes, thereby establishing a self-amplification loop that facilitates and empowers the pro-invasive functions of TGFβ. These cooperative pro-oncogenic functions of EGFR, AP-1, p63, and TGFβ were efficiently inhibited by clinically relevant chemical inhibitors. Our findings may, therefore, be of importance for therapy of patients with breast cancers with an activated EGFR-RAS-RAF pathway.


  • Open Access

    JNK-Dependent cJun Phosphorylation Mitigates TGFβ- and EGF-Induced Pre-Malignant Breast Cancer Cell Invasion by Suppressing AP-1-Mediated Transcriptional Responses

    by Anders Sundqvist, Oleksandr Voytyuk, Mohamed Hamdi, Herman E. Popeijus, Corina Bijlsma-Van der Burgt, Josephine Janssen, John W.M. Martens, Aristidis Moustakas, Carl-Henrik Heldin, Peter Ten Dijke, et al.

    Transforming growth factor-β (TGFβ) has both tumor-suppressive and tumor-promoting effects in breast cancer. These functions are partly mediated through Smads, intracellular transcriptional effectors of TGFβ. Smads form complexes with other DNA-binding transcription factors to elicit cell-type-dependent responses. Previously, we found that the collagen invasion and migration of pre-malignant breast cancer cells in response to TGFβ and epidermal growth factor (EGF) critically depend on multiple Jun and Fos components of the activator protein (AP)-1 transcription factor complex. Here we report that the same process is negatively regulated by Jun N-terminal kinase (JNK)-dependent cJun phosphorylation. This was demonstrated by analysis of phospho-deficient, phospho-mimicking, and dimer-specific cJun mutants, and experiments employing a mutant version of the phosphatase MKP1 that specifically inhibits JNK. Hyper-phosphorylation of cJun by JNK strongly inhibited its ability to induce several Jun/Fos-regulated genes and to promote migration and invasion. These results show that MEK-AP-1 and JNK-phospho-cJun exhibit distinct pro- and anti-invasive functions, respectively, through differential regulation of Smad- and AP-1-dependent TGFβ target genes. Our findings are of importance for personalized cancer therapy, such as for patients suffering from specific types of breast tumors with activated EGF receptor-Ras or inactivated JNK pathways.


  • Open Access

    JUNB governs a feed-forward network of TGFβ signaling that aggravates breast cancer invasion

    by Anders Sundqvist, Masato Morikawa, Jiang Ren, Eleftheria Vasilaki, Natsumi Kawasaki, Mai Kobayashi, Daizo Koinuma, Hiroyuki Aburatani, Kohei Miyazono, Carl-Henrik Heldin, et al.

    It is well established that transforming growth factor-β (TGFβ) switches its function from being a tumor suppressor to a tumor promoter during the course of tumorigenesis, which involves both cell-intrinsic and environment-mediated mechanisms. We are interested in breast cancer cells, in which SMAD mutations are rare and interactions between SMAD and other transcription factors define pro-oncogenic events. Here, we have performed chromatin immunoprecipitation (ChIP)-sequencing analyses which indicate that the genome-wide landscape of SMAD2/3 binding is altered after prolonged TGFβ stimulation. De novo motif analyses of the SMAD2/3 binding regions predict enrichment of binding motifs for activator protein (AP)1 in addition to SMAD motifs. TGFβ-induced expression of the AP1 component JUNB was required for expression of many late invasion-mediating genes, creating a feed-forward regulatory network. Moreover, we found that several components in the WNT pathway were enriched among the late TGFβ-target genes, including the invasion-inducing WNT7 proteins. Consistently, overexpression of WNT7A or WNT7B enhanced and potentiated TGFβ-induced breast cancer cell invasion, while inhibition of the WNT pathway reduced this process. Our study thereby helps to explain how accumulation of pro-oncogenic stimuli switches and stabilizes TGFβ-induced cellular phenotypes of epithelial cells.